TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01044251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Description: 2.5 mg po bid for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab po bid for 10 days
Study: NCT00734370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy for agoraphobic participants
Description: This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exposure in vivo for agoraphobic participants
Description: This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)
Study: NCT01462643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day
Study: NCT04668573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk exercise
Description: Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
Study: NCT03883399

Intervention type: OTHER
Intervention: Survey
Description: Survey among colorectal surgeons
Study: NCT03308955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Quadratus Lumborum block
Description: Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound guided placebo Quadratus Lumborum block
Description: Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study: NCT00484094

Intervention type: DRUG
Intervention: sirolimus
Description: Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
Study: NCT01881373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHL program
Description: Multiple component environmentally focused program designed with community engagement.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Optimized CHL program
Description: CHL programs with fewer component and shorter duration.
Study: NCT02735408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Study: NCT04296110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Relaxation Therapy
Description: We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
Study: NCT01628172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster Celcius Thermacool catheter
Description: catheter-based sympathetic renal denervation
Study: NCT04597775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: hydroxychloroquine
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study: NCT03526575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study: NCT03426696

Intervention type: BEHAVIORAL
Intervention: psychological condition
Description: Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
Study: NCT03875690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of methylprednisolone
Description: Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of sodium chloride
Description: patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: electrolyte panel and glycemia performed within the first 24 hours after surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: electrolyte panel and glycemia performed within the first 24 hours after surgery.
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study: NCT01854437

Intervention type: DRUG
Intervention: Mg Oxide
Description: 250 mg orally for 4 weeks
Study: NCT02460887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated Radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study: NCT03005249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural stem cells therapy group
Description: The patients will be assigned to neural stem cells therapy group for cerebral palsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the control group
Description: The patients will be assigned to the control group for cerebral palsy.
Study: NCT00009958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01781910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acid drink supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03655483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: Full-human anti-pd-1 monoclonal antibodies
Study: NCT01892189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets
Study: NCT02050399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise
Description: The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
Study: NCT02457793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
Study: NCT04907955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with implantation of presbyopia correcting IOL
Description: cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with implantation of presbyopia correcting IOL
Description: cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with implantation of presbyopia correcting IOL
Description: cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
Study: NCT01987999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetogenins
Study: NCT02463435

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention plus olive oil
Description: Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
Study: NCT04556006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated.
Study: NCT01712373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: it is kind of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: it is placebo
Study: NCT01950494

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fiteBac Hand Sanitizer
Description: Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fiteBac Hand Sanitizer
Description: Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
Study: NCT00749060

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: with our without brace

Intervention type: PROCEDURE
Group type: OTHER
Intervention: kyphoplasty with balloons
Description: Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vertebroplasty
Description: Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
Study: NCT00853346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Study: NCT00966771

Intervention type: DRUG
Intervention: Copper T380 IUD
Description: copper T 380 IUD

Intervention type: DRUG
Intervention: Oral levonorgestrel
Description: 1.5 mg
Study: NCT02656914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irlanda-2-Association
Description: Take 10 mL every 12 hours (2x/day), oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 10 mL every 12 hours (2x/day), oral route.